Global Malignant Melanoma Drug Market & Clinical Pipeline Insight

Description: Investigators are trying to develop innovative therapeutics for the treatment of malignant melanoma with high safety and efficacy. Surgery has remained the cornerstone of cancer treatment including malignant melanoma. Cancerous region and adjoining tissue is removed to prevent it growth. Radiation therapy is also found to be effective in melanoma treatment but it causes long-term deleterious effects on body. Chemotherapeutics can prevent malignant cancer but it side effects decrease quality of life and increase morbidity. It has been found that cancerous cells develop changes to evade the effect of the therapeutics leading to less efficacy. These facts are required to be overcome in near future and investigators are trying to develop different modalities. Some progress has been made which is expected to increase the market size of malignant melanoma.

Research and development of malignant melanoma therapeutics has gained lots of attention in past few decades due to rapidly increasing incidences. Large numbers of clinical trials have been instigated to find an effective therapeutics having high safety and efficacy levels. Various products are at different stages of clinical trials which would be introduced in coming years. Their safety and efficacy is prime concern because investigators are still trying to understand exact mechanism behind factors leading to the development of malignant melanoma. For instance, signaling pathways are complex and intertwined making it difficult for investigators to rely on single approach to treat malignant melanoma. In coming years, it is expected that investigators would be able to identify these factors resulting in development of pharmacologically superior products offering higher safety and efficacy profiles.

Malignant melanoma cells have been found to have changes in genes due to which they spread across the body. It has been found that genes like BRAF are mutated in certain individuals. By blocking their activity it would be possible to prevent the development of malignant melanoma. Side-by-side, identification of aberration in such genes will allow the investigators to identify individuals with high possibility of its development. Physicians would be able to design effective therapeutic strategies to offer better medical care. Several drug target candidates have yet to be discovered and checked for their efficacy against activity of such genes. Blocking of gene activity is difficult as their expression levels keep on changing depending upon physiological activities. Most of the studies are at incipient stages which are expected to take some time in commercialization.

Many innovative therapeutics are at various phases of clinical trials for malignant melanoma treatment. They are expected to generated statistically significant data encouraging pharmaceutical companies to proceed with higher levels of confidence. The long-term effect of these innovative therapeutics is under investigation, sufficiently high safety and efficacy data will make it easy to apply for marketing approval in different countries. In few years, owing to rapidly developing clinical pipelines, innovative malignant melanoma therapeutics are expected to enter in global market leading to increase in their market size. Future commercial success of these novel products seems to be optimistic but their commercialization may take some years.

“Global Malignant Melanoma Drug Market & Clinical Pipeline Insight” Report Highlight:

- Global Malignant Melanoma Market Analysis
- Malignant Melanoma Drug Mechanism of Action
- Global Malignant Melanoma Clinical Pipeline By Company & Phase
- Global Malignant Melanoma Clinical Pipeline: 201 Drugs
- Majority Malignant Melanoma Drugs in Preclinical Phase: 63 Drugs
- Global Malignant Melanoma Marketed Drugs Clinical Insight
- Marketed Malignant Melanoma Drugs: 25 Drugs

Contents:

1. Introduction to Malignant Melanoma
2. Malignant Melanoma Drug Mechanism of Action
3. Global Malignant Melanoma Market Analysis
3.1 Current Market Scenario
3.2 Global Malignant Melanoma Pipeline Overview

4. Global Malignant Melanoma Drug Market Dynamics
4.1 Favorable Market Parameters
4.2 Commercialization Challenges

5. Global Malignant Melanoma Drug Market Future Prospects

6. Global Malignant Melanoma Clinical Pipeline By Company & Phase
6.1 Unknown
6.2 Research
6.3 Preclinical
6.4 Clinical
6.5 Phase-I
6.6 Phase-I/II
6.7 Phase-II
6.8 Phase-II/III
6.9 Phase-III
6.10 Registered

7. Global Malignant Melanoma Marketed Drugs Clinical Insight
7.1 Talimogene Laherparepvec (IMLYGIC)
7.2 Nivolumab (Opdivo)
7.3 Temozolomide (Temodal & Temodar)
7.4 Peginterferon alfa-2b (Cylatron, Intron A Peg, PEG-Intron A, Pegatron, Pegtron, Pegtron & ViraferonPeg)
7.5 Pembrolizumab (Keytruda)
7.6 Vemurafenib
7.7 Ipilimumab (Yervoy)
7.8 Cobimetinib (Cotellic)
7.9 Trametinib (Mekinist)
7.10 Tc 99m Tilmanocept (Lymphoseek)
7.11 Dabrafenib (Tafinlar)
7.12 Aldesleukin (Chiron IL-2 & Proleukin)
7.13 Interferon alpha-2b (Intron A, Viraferon & Virtron)
7.14 Interferon-beta-1b - Toray/Daiichi Sankyo (Feron)
7.15 Melanoma Vaccine - AVAX Technologies (MVax)
7.16 Interferon alpha - Swedish Orphan Biovitrim (Multiferon)
7.17 Interferon alpha-2b - Beijing Kawin Technology
7.18 Virulizin (Virulizin)
7.19 Vemurafenib Companion Diagnostic - Roche/Plexxikon (cobas 4800 BRAF V600 Mutation Test)
7.20 Dabrafenib-Trametinib Companion Diagnostic - bioMerieux/ GlaxoSmithKline/Response Genetics (THxID-BRAF)
7.21 Interferon alpha-2b Biosimilar - Reliance Life Sciences (ReliFeron)
7.22 Technetium Tc 99m Sulfur Colloid Injection – Pharmalucence
7.23 Interferon alpha-2a (Roferon-A)
7.24 Fotemustine (Muforan, Muphoran, Mustoforan & Mustophoran)
7.25 Melanoma Vaccine – GlaxoSmithKline (Melacine)

8. Competitive Landscape
8.1 AB Science
8.2 Celgene Corporation (Abraxis BioScience)
8.3 Array BioPharma
8.4 AVAX Technologies
8.5 Biogen Idec
8.6 BioVex
8.7 Bristol-Myers Squibb
8.8 Enzon Pharmaceuticals
8.9 Eisai Co
8.10 Exelixis
8.11 GlaxoSmithKline
8.12 Lorus Therapeutics (Aptose Bioscience)
8.13 Medarex
8.14 Merck
8.15 Navidea Biopharmaceuticals
8.16 Novartis
8.17 Ono Pharmaceutical
8.18 Onyx Pharmaceuticals
8.19 Pfizer
8.20 Pharmalucence (Sun Pharmaceutical Industries Limited)
8.21 Plexxikon
8.22 QIAGEN
8.23 Roche
8.24 Reliance Life Sciences
8.25 Servier
8.26 TC BioPharm
8.27 Viragen

List of Figures:
Figure 1-1: Causes behind Development of Skin Cancer
Figure 1-2: Different Melanomas on the basis of Histology
Figure 2-1: Mechanism of Dacarbazine
Figure 2-2: Mechanism of Vemurafenib
Figure 2-3: Mechanism of Ipilimumab
Figure 2-4: Mechanism of Nivolumab
Figure 3-1: Global Malignant Melanoma Drug Market (US$ Billion), 2015-2020
Figure 3-2: Global Malignant Melanoma Drug Pipeline by Phase (%), 2016
Figure 3-3: Global Malignant Melanoma Drug Pipeline by Phase (Numbers), 2016
Figure 4-1: Malignant Melanoma Drug Market Favorable Features
Figure 4-2: Malignant Melanoma Drug Market Commercialization Challenges
Figure 8-1: AB Science Clinical Pipeline
Figure 8-2: Malignant Melanoma Clinical Pipeline
Figure 8-3: Aptose Biosciences Pipeline
Figure 8-4: Merck Clinical Pipeline
Figure 8-5: Novartis Clinical Pipeline
Figure 8-6: Plexxikon Clinical Pipeline
Figure 8-7: Roche Clinical Pipeline

Ordering:
Order Online - http://www.researchandmarkets.com/reports/3704315/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Malignant Melanoma Drug Market & Clinical Pipeline Insight
Web Address: http://www.researchandmarkets.com/reports/3704315/
Office Code: SCH3JAQW

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 2400</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 2800 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 3600 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 4800</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: 
Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: __________________________ Last Name: __________________________
Email Address: * __________________________
Job Title: __________________________
Organisation: __________________________
Address: __________________________
City: __________________________
Postal / Zip Code: __________________________
Country: __________________________
Phone Number: __________________________
Fax Number: __________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

- Account number: 833 130 83
- Sort code: 98-53-30
- Swift code: ULSBIE2D
- IBAN number: IE78ULSB98533083313083
- Bank Address: Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World